217 related articles for article (PubMed ID: 22608542)
1. Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
Guérin O; Etienne-Grimaldi MC; Monteverde M; Sudaka A; Brunstein MC; Formento P; Lattanzio L; Maffi M; Tonissi F; Ortholan C; Pagès G; Fischel JL; Lo Nigro C; Merlano M; Milano G
Urol Oncol; 2013 Nov; 31(8):1567-75. PubMed ID: 22608542
[TBL] [Abstract][Full Text] [Related]
2. Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.
Monteverde M; Tonissi F; Fischel JL; Etienne-Grimaldi MC; Milano G; Merlano M; Lo Nigro C
Urol Oncol; 2013 Aug; 31(6):776-86. PubMed ID: 21795074
[TBL] [Abstract][Full Text] [Related]
3. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
Siegfried JM; Gubish CT; Rothstein ME; Henry C; Stabile LP
J Thorac Oncol; 2012 Mar; 7(3):485-95. PubMed ID: 22258476
[TBL] [Abstract][Full Text] [Related]
4. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
[TBL] [Abstract][Full Text] [Related]
5. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Gustafson DL; Frederick B; Merz AL; Raben D
Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
Ciardiello F; Caputo R; Damiano V; Caputo R; Troiani T; Vitagliano D; Carlomagno F; Veneziani BM; Fontanini G; Bianco AR; Tortora G
Clin Cancer Res; 2003 Apr; 9(4):1546-56. PubMed ID: 12684431
[TBL] [Abstract][Full Text] [Related]
7. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
Lyros O; Mueller A; Heidel F; Schimanski CC; Gockel I; Galle PR; Lang H; Moehler M
Int J Cancer; 2010 Sep; 127(5):1197-208. PubMed ID: 20039326
[TBL] [Abstract][Full Text] [Related]
8. Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.
Ichihara E; Ohashi K; Takigawa N; Osawa M; Ogino A; Tanimoto M; Kiura K
Cancer Res; 2009 Jun; 69(12):5091-8. PubMed ID: 19491268
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.
Bianco R; Rosa R; Damiano V; Daniele G; Gelardi T; Garofalo S; Tarallo V; De Falco S; Melisi D; Benelli R; Albini A; Ryan A; Ciardiello F; Tortora G
Clin Cancer Res; 2008 Aug; 14(16):5069-80. PubMed ID: 18694994
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.
Gule MK; Chen Y; Sano D; Frederick MJ; Zhou G; Zhao M; Milas ZL; Galer CE; Henderson YC; Jasser SA; Schwartz DL; Bankson JA; Myers JN; Lai SY
Clin Cancer Res; 2011 Apr; 17(8):2281-91. PubMed ID: 21220477
[TBL] [Abstract][Full Text] [Related]
12. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
Brave SR; Odedra R; James NH; Smith NR; Marshall GB; Acheson KL; Baker D; Howard Z; Jackson L; Ratcliffe K; Wainwright A; Lovick SC; Hickinson DM; Wilkinson RW; Barry ST; Speake G; Ryan AJ
Int J Oncol; 2011 Jul; 39(1):271-8. PubMed ID: 21537841
[TBL] [Abstract][Full Text] [Related]
13. Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.
Choi S; Sano D; Cheung M; Zhao M; Jasser SA; Ryan AJ; Mao L; Chen WT; El-Naggar AK; Myers JN
Clin Cancer Res; 2008 Aug; 14(16):5081-9. PubMed ID: 18698025
[TBL] [Abstract][Full Text] [Related]
14. Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.
Sasaki T; Tanno S; Shibukawa K; Osanai S; Kawabe J; Ohsaki Y
Int J Oncol; 2008 Sep; 33(3):525-32. PubMed ID: 18695882
[TBL] [Abstract][Full Text] [Related]
15. KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
Nilsson MB; Giri U; Gudikote J; Tang X; Lu W; Tran H; Fan Y; Koo A; Diao L; Tong P; Wang J; Herbst R; Johnson BE; Ryan A; Webster A; Rowe P; Wistuba II; Heymach JV
Clin Cancer Res; 2016 Apr; 22(8):1940-50. PubMed ID: 26578684
[TBL] [Abstract][Full Text] [Related]
16. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
Morabito A; Piccirillo MC; Falasconi F; De Feo G; Del Giudice A; Bryce J; Di Maio M; De Maio E; Normanno N; Perrone F
Oncologist; 2009 Apr; 14(4):378-90. PubMed ID: 19349511
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
Wachsberger PR; Lawrence YR; Liu Y; Daroczi B; Xu X; Dicker AP
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):483-91. PubMed ID: 21095630
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
Lin J; Wu H; Shi H; Pan W; Yu H; Zhu J
PLoS One; 2013; 8(10):e76169. PubMed ID: 24155892
[TBL] [Abstract][Full Text] [Related]
19. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
Sano D; Matsumoto F; Valdecanas DR; Zhao M; Molkentine DP; Takahashi Y; Hanna EY; Papadimitrakopoulou V; Heymach J; Milas L; Myers JN
Clin Cancer Res; 2011 Apr; 17(7):1815-27. PubMed ID: 21350000
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]